Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Beta Bionics (BBNX) Total Non-Current Liabilities (2023 - 2025)

Beta Bionics (BBNX) has disclosed Total Non-Current Liabilities for 3 consecutive years, with $39.6 million as the latest value for Q4 2025.

  • Quarterly Total Non-Current Liabilities rose 37.77% to $39.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $39.6 million through Dec 2025, up 37.77% year-over-year, with the annual reading at $39.6 million for FY2025, 37.77% up from the prior year.
  • Total Non-Current Liabilities hit $39.6 million in Q4 2025 for Beta Bionics, up from $34.1 million in the prior quarter.
  • In the past five years, Total Non-Current Liabilities ranged from a high of $39.6 million in Q4 2025 to a low of $13.9 million in Q4 2023.
  • Historically, Total Non-Current Liabilities has averaged $27.9 million across 3 years, with a median of $28.0 million in 2024.
  • Biggest five-year swings in Total Non-Current Liabilities: surged 107.33% in 2024 and later skyrocketed 37.77% in 2025.
  • Year by year, Total Non-Current Liabilities stood at $13.9 million in 2023, then surged by 107.33% to $28.7 million in 2024, then surged by 37.77% to $39.6 million in 2025.
  • Business Quant data shows Total Non-Current Liabilities for BBNX at $39.6 million in Q4 2025, $34.1 million in Q3 2025, and $27.3 million in Q2 2025.